Seriday Apr 2026

Developed by the biotechnology company , it was specifically designed to treat Gaucher disease , a rare genetic condition where patients lack a critical enzyme to break down fatty substances in their cells. Key Facts About Seriday

: It represented a shift in medical treatment, moving from managing symptoms to replacing the missing biological component (alglucerase) directly in the body. Seriday

(also known as Ceredase) is a landmark in pharmaceutical history as the first enzyme replacement therapy (ERT) approved by the FDA in 1991. Developed by the biotechnology company , it was